The global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to USD 157.5 billion by 2035, at a CAGR of 9.7% during the forecast period, till 2035.
Lately, GLP-1 drugs have emerged as a promising option. Significantly, 15 GLP-1 drugs have been introduced for treating various conditions. In addition, more than 135 drug candidates are currently being evaluated across various development stages. GLP-1 drugs boost insulin release in response to glucose, lowering blood sugar levels without notably raising the risk of hypoglycemia. They delay gastric emptying and inhibit glucagon secretion, enhancing glycemic regulation in individuals with type 2 diabetes. GLP-1 agonists enhance feelings of fullness, decrease hunger, and delay gastric emptying, resulting in significant weight reduction. Clinical trials, including the STEP program for semaglutide, showed weight reduction of 15-20% of body weight in individuals with obesity, significantly exceeding standard weight loss methods.
This positions them as a transformative solution for obesity management, tackling a worldwide health emergency. Additionally, GLP-1 medications lower the likelihood of significant adverse cardiovascular events, including heart attacks and strokes, in individuals with type 2 diabetes or elevated cardiovascular risk.
The efficacy of GLP-1 medications in weight management presents opportunities for wider application in non-diabetic groups, combating the worldwide obesity crisis. Improvements in drug administration, including implantable devices, extended-release formulations, or non-invasive methods (like transdermal patches), may enhance patient satisfaction and broaden market appeal Impacted by recent drug approvals (for diverse applications) and substantial R&D investments from companies (to enhance delivery systems for GLP-1 drugs), the market is projected to witness steady growth in the coming decade.
GLP-1 Market: Growth and Trends
The World Health Organization (WHO) states that more than 1 billion individuals worldwide are impacted by obesity, comprising 650 million adults. Moreover, it is estimated that 4 million people lose their lives annually due to obesity. Moreover, a recent study indicates that around 530 million adults globally are affected by diabetes, with 98% individuals within this group expected to have type 2 diabetes. Due to the rising rates of obesity and diabetes, there is a growing need for effective and reliable treatments. As a result, numerous companies have started developing and evaluating possible candidates for these indications.Lately, GLP-1 drugs have emerged as a promising option. Significantly, 15 GLP-1 drugs have been introduced for treating various conditions. In addition, more than 135 drug candidates are currently being evaluated across various development stages. GLP-1 drugs boost insulin release in response to glucose, lowering blood sugar levels without notably raising the risk of hypoglycemia. They delay gastric emptying and inhibit glucagon secretion, enhancing glycemic regulation in individuals with type 2 diabetes. GLP-1 agonists enhance feelings of fullness, decrease hunger, and delay gastric emptying, resulting in significant weight reduction. Clinical trials, including the STEP program for semaglutide, showed weight reduction of 15-20% of body weight in individuals with obesity, significantly exceeding standard weight loss methods.
This positions them as a transformative solution for obesity management, tackling a worldwide health emergency. Additionally, GLP-1 medications lower the likelihood of significant adverse cardiovascular events, including heart attacks and strokes, in individuals with type 2 diabetes or elevated cardiovascular risk.
The efficacy of GLP-1 medications in weight management presents opportunities for wider application in non-diabetic groups, combating the worldwide obesity crisis. Improvements in drug administration, including implantable devices, extended-release formulations, or non-invasive methods (like transdermal patches), may enhance patient satisfaction and broaden market appeal Impacted by recent drug approvals (for diverse applications) and substantial R&D investments from companies (to enhance delivery systems for GLP-1 drugs), the market is projected to witness steady growth in the coming decade.
GLP-1 Market: Key Insights
The report delves into the current state of the GLP-1 market and identifies potential growth opportunities within the industry. Some key findings from the report include:
- More than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies.
- ~60% of the GLP-1 drug candidates are currently being evaluated in clinical stages of development; of these, most of the candidates target metabolic disorders, such as Type 2 diabetes and obesity.
- The current market landscape of GLP-1 drugs is fragmented, featuring the presence of both new entrants and established players; majority of these firms are based in China (36%) and the US (28%).
- Partnerships related to GLP-1 drugs have steadily grown in the recent past; notably, close to 50% of these deals were signed for drug development and commercialization.
- Lifestyle changes, influence of social media, celebrity endorsements and direct to consumer advertisements have led to a surge in the demand for GLP-1 drugs.
- The GLP-1 market is anticipated to grow at a CAGR of 9.7%, during the forecasted period; biologics segment is expected to capture the majority share (over 65%) of the market by 2035.
GLP-1 Market: Key Segments
Currently, Small Molecule Segment Occupies the Largest Share of the GLP-1 Market
In terms of type of molecule, the market is segmented into biologics and small molecules. Currently, the small molecules category occupies the largest share of the GLP-1 market. It is important to emphasize that due to the distinct physiological characteristics of biologics, such as stability, specificity, selectivity, and capacity to inhibit particular protein-protein interactions, the biologics sector is expected to expand at a comparatively higher CAGR.Survodutide Active Compound is the Fastest Growing Segment of the GLP-1 Market During the Forecast Period
In terms of the active compound, the market is segmented into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds. At present, semaglutide holds the maximum share of the GLP-1 market. Further, it is worth highlighting that survodutide is likely to drive the market in the near future.Currently, Long-Acting GLP-1 Agonists Occupies the Largest Share of the GLP-1 Market
In terms of the type of GLP-1 agonists drugs, the market is segmented into short-acting GLP-1 agonist and long-acting GLP-1 agonist. Currently, long-acting GLP-1 agonists dominate the GLP-1 market, and this trend is expected to persist in the coming years. This is due to the longer duration of effect of the long-acting medication compared to short-acting agonists. It's important to note that the short-acting GLP-1 agonist segment is expected to expand at a notably higher CAGR.At Present, Single-agonist Segment Occupies the Largest Share of the GLP-1 Market
In terms of the type of GLP-1 agonist, the market is segmented into single-agonist, dual-agonist and tri-agonist. Currently, the single-agonist segment holds the maximum share of the GLP-1 market. It is worth highlighting that tri-agonist segment is likely to grow at a relatively higher CAGR.Oral Route of Administration is the Fastest Growing Segment in the GLP-1 Market During the Forecast Period
In terms of the route of administration, the market is segmented into oral route and parenteral route. At present, the parenteral route holds a larger share of the GLP-1 market. This trend is likely to remain the same in the coming decade. Further, it is worth noting that oral route of administration is likely to grow at a relatively higher CAGR.Type 2 Diabetes Segment Accounts for the Largest Share of the GLP-1 Market
In terms of the target indication, the market is segmented into Alzheimer’s Disease, non-alcoholic steatohepatitis, obesity, sleep apnea, and type 2 diabetes. Although type 2 diabetes represents a larger market share, it is important to note that the non-alcoholic steatohepatitis segment is anticipated to experience significant market expansion in the years ahead.North America Accounts for the Largest Share of the Market
In terms of the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Latin America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.Example Players in the GLP-1 Market
- AstraZeneca
- Biolingus
- Boehringer Ingelheim
- D&D Pharmatech
- Eli Lilly
- Gmax Biopharm
- Hanmi Pharmaceutical
- Innogen
- Novo Nordisk
- PegBio
- Pfizer
- QL Biopharma
- Roche
- Sanofi
- Sciwind Biosciences
- Tonghua Dongbao Pharmaceutical
- Viking Therapeutics
- Vivani
- vTv Therapeutic
GLP-1 Market: Research Coverage
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the GLP-1 market, focusing on key market segments, including [A] type of molecule, [B] active compound used, [C] type of GLP-1 agonist drugs, [D] type of agonist, [E] target indication and [F] geographical regions.
- Market Landscape: A comprehensive evaluation of GLP-1 drugs, considering various parameters, such as [A] stage of development, [B] type of molecule, [C] active compound used, [D] GLP-1 agonist, [E] route of administration, [F] dosing frequency, [G] type of therapy, [H] target indication and [I] therapeutic area. Additionally, it provides a detailed list of developers engaged in developing GLP-1 drugs, along with information on various parameters, such as [J] year of establishment, [K] company size (in terms of employee count) and [L] location of headquarters.
- Company Profiles: In-depth profiles of key industry players engaged in the development of GLP-1 drugs, focusing on [A] company overviews, [B] financial information, [C] drug portfolio, [D] recent developments and [E] an informed future outlook.
- Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2020, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] type of partner, [E] most active players (in terms of the number of partnerships signed) and [F] regional distribution of partnership activity in this domain.
- Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.
Key Questions Answered in this Report
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
Additional Benefits
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with the Research Team
- Free Update if the Report is 6+ Months Old
Table of Contents
1 BACKGROUND
2. RESEARCH METHODOLOGY
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
5. INTRODUCTION
6. MARKET LANDSCAPE: GLP-1 DRUGS
7. GLP-1 DRUGS: DETAILED COMPANY PROFILES
8. GLP-1 DRUGS: BRIEF COMPANY PROFILES
9. PARTNERSHIPS AND COLLABORATIONS
10. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
11. GLOBAL GLP-1 MARKET
12. GLP-1 MARKET, BY TYPE OF MOLECULE
13. GLP-1 MARKET, BY ACTIVE COMPOUND USED
14. GLP-1 MARKET, BY TYPE OF GLP-1 AGONIST DRUGS
15. GLP-1 MARKET, BY GLP-1 AGONIST
16. GLP-1 MARKET, BY ROUTE OF ADMINISTRATION
17. GLP-1 MARKET, BY TARGET INDICATION
18. GLP-1 MARKET, BY GEOGRAPHY
19. GLP-1 MARKET, SALES FORECAST OF GLP-1 DRUGS
20. GLP-1 MARKET, BY LEADING DRUG DEVELOPERS
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4P-Pharma
- Adocia
- Alphamab
- Altimmune
- Amazon
- Amgen
- Arecor Therapeutics
- AstraZeneca
- Beijing Dongfang Biotech
- Shanghai Benemae Pharmaceutical
- Biocon
- Biolingus
- Biomm
- BNC KOREA
- Boehringer Ingelheim
- BrightGene Bio-Medical Technology
- Carmot Therapeutics
- Catalent
- Cipla
- Colorcon Ventures
- D&D Pharmatech
- DCP Capital
- Zhejiang Doer Biologics
- Dong-A Pharmaceutical
- Eccogene
- Eiger BioPharmaceuticals
- Eli Lilly
- Emisphere Technologies
- Entera Bio
- Flagship Pioneering
- Gan & Lee Pharmaceuticals
- Genexine
- Gmax Biopharm
- Hanmi Pharmaceutical
- Hansoh Pharma
- HK inno.N
- Huadong Medicine
- i2o Therapeutics
- IlDong Pharmaceutical
- ImmunoForge
- Innogen
- Invex Therapeutics
- Jiangsu Hengrui Pharmaceuticals
- Kariya Pharmaceuticals
- Kexing Biopharm
- LeaderMed
- Merck
- Metsera
- MindRank
- Mitsubishi Tanabe Pharma
- Nano Precision Medical
- Neuraly
- NeuroBo Pharmaceuticals
- Nexus Pharmaceuticals
- Novo Nordisk
- OPKO Health
- Oramed Pharmaceuticals
- PegBio
- Peptron
- Pfizer
- PROGEN
- Beijing QL Biopharmaceutica
- Rani Therapeutics
- Regor Pharmaceuticals
- Roche
- Sanofi
- Sciwind Biosciences
- SCOHIA PHARMA
- Second Sight
- Shanghai Minwei Biotechnology
- Shenzhen Salubris Pharmaceuticals
- Sino Biopharmaceutical
- Sinovac Biotech
- Structure Therapeutics
- Sun Pharmaceutical
- Terns Pharmaceuticals
- Tonghua Dongbao Pharmaceutical
- TRx Biosciences
- Uni-Bio Science
- United Laboratories
- Versanis Bio (acquired by Eli Lilly and Company)
- Viking Therapeutics
- Vivani Medical
- vTv Therapeutics
- Ypsomed
- Yuhan
- Zealand Pharma
Methodology
LOADING...
